BioWorld

March 14, 2005

Savient Terminates Phase II Prosaptide Analgesia Study

Savient Pharmaceuticals Inc. has halted its Phase II trial for Prosaptide after an interim analysis indicated the product would not reach its analgesia efficacy endpoint. (BioWorld Today) Read More

XOMA Anti-Terrorism Deal Provides Needed Stock Hike

Survival Of Fittest In 2005 For Biotechnology Firms

Raising $7M, ImaRx Plans To Fund Trials, Add Executives

Republicans, Democrats Detail Health Care Agendas For 2005

Other News To Note

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for Aug. 6, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for August 6, 2025.

Chimerix buyout a win for Jazz with FDA nod for rare glioma drug

BioWorld

Jazz Pharmaceuticals plc is prepped and ready for launch following U.S. FDA accelerated approval of dordaviprone as the first systemic therapy for H3 K27M-mutant...

FDA defends use of PFAS in medical devices

BioWorld MedTech

The U.S. FDA has staked out a position on the use of per- and polyfluoroalkyl substances in medical devices, declaring that the evidence offers no reason to...

Illustration of Microglia cells (red) in Alzheimer´s disease

Two cancer drugs combined modify Alzheimer’s disease in mice

BioWorld

Current treatments for Alzheimer’s disease have limited effects. While they can slow cognitive decline or alleviate symptoms, they do not reverse this complex...